Skip to main content

Advertisement

SpringerLink
Log in

In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFNα treatment

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Eighteen patients with myeloproliferative syndrome (14 with chronic myeloid leukemia, four with essential thrombocytosis) were investigated for modulation of HLA antigens on peripheral blood lymphocytes, monocytes, and hematopoietic precursors during IFNα therapy as a sign of potentially increased immune recognition of malignant cells. After 1 month of IFNα therapy, an increased number of monocytes and hematopoietic precursor cells, but not of lymphocytes, expressed HLADQ antigens. In addition, a strong induction of HLA class-I antigens was found on both hematopoietic progenitors and normal peripheral blood mononuclear cells. With daily injections of IFN in the first month of therapy stimulation continuously increased, suggested a major effect of IFNa on hematopoietic progenitors with sustained enhanced expression of HLA class-I antigens during differentiation of myelomonocytic cells. HLA class-I antigen expression was consistently augmented by IFNα in all patients, irrespective of their hematological response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abi-Hanna D, Wakefield D (1990) Differential enhancement of HLA-B27 by interferon. Hum Immunol 27: 33–39

    PubMed  Google Scholar 

  2. Barnstable CJ, Bodmer WF, Brown G, Galfr G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group-A erythrocytes, HLA and other human cell surface antigens — new tools for genetic analysis. Cell 14: 9–20

    PubMed  Google Scholar 

  3. Bergsagel DE (1988) Interferon α-2b in the management of chronic granulocytic leukemia. Cancer Treat Rep 15 [Suppl A]: 15–20

    Google Scholar 

  4. Burrone OR, Kefford RF, Gilmore D, Milstein C (1985) Stimulation of HLA-A, B, C by IFN-α. The derivation of Molt 4 variants and the differential expression of HLA-A, B, C subsets. EMBO J 4: 2855–2860

    PubMed  Google Scholar 

  5. Eric TE, Scornik JC, Davis G, Kao KJ (1990) Induction of erythrocyte HLA expression during interferon treatment and HIV infection. Hum Immunol 29: 14–22

    PubMed  Google Scholar 

  6. Gastl G, Huber C (1988) The biology of interferon actions. Blut 56: 193–199

    PubMed  Google Scholar 

  7. Gressler VH, Weinkauff RE, Franklin WA, Golomb HM (1988) Modulation of the expression of major histocompatibility antigens on splenic hairy cells — differential effect upon in vitro treatment with α-2b-interferon, γ-interferon, and interleukin-2. Blood 72: 1048–1053

    PubMed  Google Scholar 

  8. Hakem R, Le Bouteiller P, Barad M, Trujillo M, Mercier P, Wietzerbin J, Lemonnier FA (1989) IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A 3 class-I genes. J Immunol 142: 297–305

    PubMed  Google Scholar 

  9. Heidemann E, Weber J, Schmidt H, Reichmann U (1986) Recombinant interferonα 2 stimulation of target-binding by natural killer cells. Klin Wochenschr 64: 1036–1040

    PubMed  Google Scholar 

  10. Heron I, Hokland M, Berg K (1978) Enhanced expression of β 2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 75: 6215–6219

    PubMed  Google Scholar 

  11. Lotzova E, Savary CA, Gutterman JU, Hersh EM (1982) Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α. Cancer Res 42: 2480–2488

    PubMed  Google Scholar 

  12. Müller C, Liangru S, Schneider M, Ziegler A, Wernet P (1983) A cytotoxic monoclonal IgM antibody (Tü 101) directed against an antigenic determinant shared between the HLA-A allospecificities A2 and A28. Hum Immunol 6: 189–197

    PubMed  Google Scholar 

  13. Müller C, Ziegler A, Muller C, Hadam M, Waller HD, Wernet P, Müller G (1985) Divergent expression of HLA-DC/MB, -DR, and -SB region products on normal and pathological tissues as detected by monoclonal antibodies. Immunobiology 169: 228–249

    PubMed  Google Scholar 

  14. Müller GA, Müller C, Risler T (1984) Charakterisierung glomerulärer Halbmonde bei rapid progressiver Glomerulonephritis (RPGN) mit Hilfe monoklonaler Antikörper. Verh Dtsch Ges Inn Med 90: 1013–1016

    Google Scholar 

  15. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG (1987) Interferon α-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14: 29–35

    Google Scholar 

  16. Nissen MH, Larsen JK, Plesner T, Olesen BK, Ernst P (1987) α-interferon induces enhanced expression of HLA-ABC antigens and β 2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells. Clin Exp Immunol 69: 632–638

    PubMed  Google Scholar 

  17. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Ann Rev Biochem 56: 727–777

    PubMed  Google Scholar 

  18. Rosa FM, Cochet MM, Fellous M (1986) Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation? Interferon 7: 47–87

    PubMed  Google Scholar 

  19. Roth TE, Foon KA (1986) α-interferon in the treatment of hematologic malignancies. Am J Med 81: 871–882

    PubMed  Google Scholar 

  20. Schmidt H, Forsthuber T, Bühring H-J, Müller CA (1987) Differential expression of the HLA-B 7 and HLA-A 2 gene in transfected mouse L (tk-) cells after stimulation by mouse interferon. Immunobiology 174: 51–66

    PubMed  Google Scholar 

  21. Schmidt H, Steinke B, Zinser R, Frese G, Gehr C, Gekeler V, Waller HD (1989) Interferon-α in the treatment of chronic myeloid leukemia and essential thrombocytosis: differences in response rate between untreated patients and patients pretreated with busulfan. Tumor Diagn Ther 10: 257–261

    Google Scholar 

  22. Schmidt H, Gekeler V, Haas H, Engler-Blum G, Steiert I, Probst H, Müller CA (1990) Differential regulation of HLA class-I genes by interferon. Immunogenetics 31: 245–252

    PubMed  Google Scholar 

  23. Spring G, Pawelec G, Ziegler A (1986) Gamma ray-induced mutants as a tool for the production and characterization of monoclonal antibodies against HLA alloantigens. Tissue Antigens 27: 201–208

    PubMed  Google Scholar 

  24. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692

    PubMed  Google Scholar 

  25. Talpaz M, Trujillo JM, Hittelman WN, Keating MJ, Gutterman JU (1985) Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon. Br J Haematol 60: 619–624

    PubMed  Google Scholar 

  26. Talpaz M, Kantarijan H, Kurzrock R, Gutterman J (1988) Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 25: 62–73

    PubMed  Google Scholar 

  27. Tanaka K, Yoshioka T, Bieberich C, Jay G (1988) Role of the major histocompatibility complex class-I antigens in tumor growth and metastasis. Ann Rev Immunol 6: 359–380

    Google Scholar 

  28. Watson AJ, DeMars R, Towbridge IS, Bach FH (1983) Detection of a novel human class-II HLA-antigen. Nature 304: 358–361

    PubMed  Google Scholar 

  29. Yang SY, Morishima Y, Collins NH, Alton T, Pollack MS, Yunis EJ, Dupont B (1984) Comparison of one-dimensional IEF patterns for serologically detectable HLA-A and -B allotypes. Immunogenetics 19: 217–231

    PubMed  Google Scholar 

  30. Ziegler A, Heinig J, Müller C, Gitz H, Thinnes FP, Uchanska-Ziegler B, Wernet P (1986) Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies Tü 22, 34, 36, 37, 39, 43, 58 and YD 1/63.HLK directed against human HLA class-II antigens. Immunobiology 171-77-92

Download references

Author information

Authors and Affiliations

  1. Abteilung II, Medizinische Klinik und Poliklinik, Otfried-Müller-Strasse 10, W-7400, Tübingen, Federal Republic of Germany

    C. A. Müller, J. Walz, R. Zinser, H. J. Bühring, B. Steinke & H. Schmidt

Authors
  1. C. A. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Walz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Zinser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. J. Bühring
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Steinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by theElse Übelmesser Stiftung and theDeutsche Forschungsgemeinschaft, Sonderforschungsbereich 120, projects A3 and D4

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, C.A., Walz, J., Zinser, R. et al. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFNα treatment. Ann Hematol 63, 259–263 (1991). https://doi.org/10.1007/BF01698375

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01698375

Key words

Search

Navigation